ORAL TREATMENT OF HEMOPHILIA

Disclosed herein is a simple method for the treatment of antigen-deficiency diseases, by orally administering to a subject a therapeutically effective amount of the deficient antigen, wherein the antigen is not present in a liposome. In one embodiment, the method increases hemostasis in a subject having hemophilia A or B, by orally administering to the hemophiliac a therapeutically effective amount of the appropriate clotting factor other than in a liposome, sufficient to induce oral tolerance and supply exogenous clotting factor to the subject

INDUCTION OF TOLERANCE BY ORAL ADMINISTRATION OF FACTOR VIII AND TREATMENT OF HEMOPHILA

Disclosed herein is a simple method for the treatment of antigen-deficiency diseases, by orally administering to a Subject a therapeutically effective amount of the deficient anti gen, wherein the antigen is not present in a liposome. In one embodiment, the method increases hemostasis in a subject having hemophilia A or B, by orally administering to the hemophiliac atherapeutically effective amount of the appropriate clotting factor other than in a liposome, Sufficient to induce oral tolerance and Supply exogenous clotting factor to the subject

ORAL TREATMENT OF HEMOPHILIA

Disclosed herein is a simple method for the treatment of antigen-deficiency diseases, by orally administering to a subject a therapeutically effective amount of the deficient antigen, wherein the antigen is not present in a liposome. In one embodiment, the method increases hemostasis in a subject having hemophilia A or B, by orally administering to the hemophiliac a therapeutically effective amount of the appropriate clotting factor other than in a liposome, sufficient to induce oral tolerance and supply exogenous clotting factor to the subject

SARS-CoV-2 specific antibody and neutralization assays reveal the wide range of the humoral immune response to virus.

Development of antibody protection during SARS-CoV-2 infection is a pressing question for public health and for vaccine development. We developed highly sensitive SARS-CoV-2-specific antibody and neutralization assays. SARS-CoV-2 Spike protein or Nucleocapsid protein specific IgG antibodies at titers more than 1:100,000 were detectable in all PCR+ subjects (n = 115) and were absent in the negative controls. Other isotype antibodies (IgA, IgG1-4) were also detected. SARS-CoV-2 neutralization was determined in COVID-19 and convalescent plasma at up to 10,000-fold dilution, using Spike protein pseudotyped lentiviruses, which were also blocked by neutralizing antibodies (NAbs). Hospitalized patients had up to 3000-fold higher antibody and neutralization titers compared to outpatients or convalescent plasma donors. Interestingly, some COVID-19 patients also possessed NAbs against SARS-CoV Spike protein pseudovirus. Together these results demonstrate the high specificity and sensitivity of our assays, which may impact understanding the quality or duration of the antibody response during COVID-19 and in determining the effectiveness of potential vaccines

Development and Validation of a Symptom-Based Activity Index for Adults With Eosinophilic Esophagitis

Standardized instruments are needed to assess the activity of eosinophilic esophagitis (EoE), to provide endpoints for clinical trials and observational studies. We aimed to develop and validate a patient-reported outcome (PRO) instrument and score, based on items that could account for variations in patients’ assessments of disease severity. We also evaluated relationships between patients’ assessment of disease severity and EoE-associated endoscopic, histologic, and laboratory findings

Düşük gürültülü güçlendirici tasarımı ve optimizasyonu

Düşük gürültülü güçlendiriciler birçok iletişim sisteminin girişindeki anahtar elemanlardır.Bu sistemler girişlerinde düşük seviyede sinyaller isterler.Düşük gürültülü güçlendiricilerin asıl amacı gürültüyü mümkün olduğunca düşük tutarak bu sinyalleri güçlendirmektir. Düşük gürültülü güçlendiricilerin performansı en çok kazanç ve gürültü oranları ile ölçülür. Bunların dışında dinamik aralığı , kararlılığı ve dönüş kaybı gibi kriterler de vardır._x000B_Tez başlangıcında silikon tunerlerin girişindeki sinyaller için güçlendirici yapmayı hedefledik.Yaptığımız birkaç araştırmadan sonra 950Mhz ile 2.1Ghz arasında gerekli kazanç ve gürültü oranı ile çalışacak bir düşük gürültülü güçlendirici yapmaya karar verdik.Öncelikle güçlendirici için gerekli olan aktif malzemeyi seçtik.Amacımız için NXP nin BFG425 RF transistörünü seçtik.Sıcaklık ve diğer çevresel etkenlerden etkilenmeden mümkün olduğunca kararlı çalışacak bir tetikleme devresi tasarladık.Transistörün giriş ve çıkışı için eşleştirme devreleri tasarladık.RF dizayn gereksinimlerine göre baskı devre tasarladık.İlk sonuçları aldıktan sonra AWR Microwave office programını kullanarak hedeflediğimiz dizayn özellikleri için devreyi optimize ettik. Low noise amplifiers are key components in the receiving end of nearly every communication system. These systems require very weak signals at the input. Primary purpose of LNA is to amplify the weak signal while keeping noise as little as possible. Performance of LNA is measured most notably by its gain and noise figure. There are also other performance criteria?s such as dynamic range, return loss and stability._x000B_At the beginning of project we aimed to design an amplifier for RF signal of satellite silicone tuners. After some observation we decided to design a LNA which works between 950 MHz to 2.1 GHz with required gain and noise figure. First of all, we selected the required active amplifier component. We chose NXP BFG 425 RF transistor for this purpose. We designed a biasing circuit which works as stable as possible regardless of temperature and other environment effects. We designed matching circuits for both input and output of this transistor. We draw PCB according to RF design requirements. After getting first measurements, we used AWR Microwave office for optimization of circuit to reach target design spec

Induction of Eosinophilic Esophagitis by Sublingual Pollen Immunotherapy

Sublingual immunotherapy (SLIT) is increasingly investigated and utilized for the treatment of food and pollen allergies. Previous case reports suggested that eosinophilic esophagitis (EoE) might develop as a long-term complication in children after completion of oral immunotherapy. Here, we describe a 44-year-old female with a medical history of pollinosis who for the first time in her life developed complete manifestation of EoE (peak eosinophils 164/high power field) 4 weeks after initiation of SLIT using specific soluble allergens (hazelnut, birch, alder) according to previous specific serum IgE testing. After discontinuation of SLIT, EoE resolved completely within 4 weeks without any other medical intervention. During a follow-up of 12 months the patient remained free of any esophageal symptoms. This is the first case report demonstrating a close and therefore likely causative association between pollen SLIT and EoE in an adult patient

INDUCTION OF TOLERANCE BY ORAL ADMINISTRATION OF FACTOR VIII AND TREATMENT OF HEMOPHILA

Disclosed herein is a simple method for the treatment of antigen-deficiency diseases, by orally administering to a Subject a therapeutically effective amount of the deficient anti gen, wherein the antigen is not present in a liposome. In one embodiment, the method increases hemostasis in a subject having hemophilia A or B, by orally administering to the hemophiliac atherapeutically effective amount of the appropriate clotting factor other than in a liposome, Sufficient to induce oral tolerance and Supply exogenous clotting factor to the subject